PEN logo

PENUMBRA INC

PENNYSE
πŸ† #695 by market capEarnings Nov 4 Β· PostUS Equity
$318.27β–Ό $5.80 (βˆ’1.79%)
Market closed Β· at close
πŸ””
Track PEN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 1.8%
7dβ–Ό 2.1%
14dβ–Ό 0.9%
30dβ–Ό 0.2%
ytdβ–² 2.2%
1yβ–² 36.2%
🏦Market Cap
$12.54B
Mid Cap
πŸ“ˆRevenue Growth (YoY)
17.6%
Healthy
πŸ“ŠGross Margin
67.8%
High
πŸ’΅FCF Margin
14.3%
Healthy
βš–οΈP/S Ratio
8.5x
Elevated
Otter Score
76
Strong

Trading Snapshot

Day Range
$316.35 – $321.15
52-Week Range
$221.26 – $362.41
Volume (shares)
134,172
Avg Volume (shares)
β€”
Shares Outstanding
39.4M
Next Earnings
2026-11-04

Fundamentals Snapshot

Annual Revenue
$1.40B
Last Q Revenue
$390M
P/E Ratio
79.7
P/S Ratio
8.5x
EPS (TTM)
$4.07
Dividend Yield
β€”
Dilution (1yr)
+0.3%
PEN logo

PENUMBRA INC

PEN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$1.4Bβ–² +17.5% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
67.1%β–² +6.2% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$189Mβ–² +119.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$175Mβ–² +18.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
39.4Mβ–² +0.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$33Mβ–Ό βˆ’$134M YoY
StockOtter Β· stockotter.space

About PENUMBRA INC

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100

Analyst Ratings

β“˜
Consensus
Hold
15 analysts
Strong Buy1
Buy4
Hold10
Sell0
Strong Sell0
Ratings as of Oct 2026

Latest News & Updates

News unavailable.